Keltic Pharma Therapeutics is pioneering a novel drug discovery platform known as PEPSMOL©, which focuses on targeting G protein-coupled receptors (GPCRs), particularly the FFA4 receptor. This receptor is identified as a promising target for treating inflammatory airway diseases, such as severe asthma, which often do not respond to traditional therapies. The PEPSMOL© platform aims to overcome the limitations of conventional small molecule screening methods, especially for GPCRs with poorly defined binding sites. By developing a new class of molecules termed "synthetic biologics," Keltic Pharma seeks to combine the beneficial properties of small molecules and biologics, such as antibodies, to create more effective treatments for unmet clinical needs.

The recent award of a SMART Grant from Innovate UK underscores the significance of Keltic Pharma's innovative approach to drug discovery. This funding will facilitate the validation of the PEPSMOL© platform against the FFA4 receptor and support the development of inhaled synthetic biologic drugs aimed at normalizing lung function and reducing inflammation in patients with severe asthma. The company's founders have already demonstrated the potential of this approach in preclinical models, and with the backing of Innovate UK, Keltic Pharma is poised to advance its research and contribute to the biotech sector's growth in the UK.

Ireland

Keltic Pharma is based in a world leading laboratory in Glasgow with our highly skilled team of industrial scientists and leading academics. We work alongside commercial partners and universities to deploy novel innovative technologies in the pursuit of next generation drugs for unmet clinical needs.

Keltic Pharma Therapeutics

Company Details